+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pharmacokinetics of losartan and its active carboxylic acid metabolite E-3174 in five ethnic populations of China



Pharmacokinetics of losartan and its active carboxylic acid metabolite E-3174 in five ethnic populations of China



Journal of Clinical Pharmacy and Therapeutics 37(2): 226-231



Interethnic variability in drug pharmacokinetics is well known. Our aim was to investigate whether the pharmacokinetics of losartan and its active carboxylic acid metabolite E-3174 vary between subjects of five Chinese ethnicities (Han, Mongolian, Korean, Hui and Uigur). Fifty healthy subjects (five men and five women of each ethnicity) were recruited, and each received 50-mg dose of losartan in tablet form. Fourteen blood samples were collected for each subject over a 24-h period after drug administration. The concentrations of losartan and its active carboxylic acid metabolite E-3174 in plasma were determined by high-performance liquid chromatography/fluorescence (HPLC/FLU) method, and the pharmacokinetic parameters were calculated by DAS 2.0 software and compared by SPSS 16.0 software. Pharmacokinetic parameters, including area under the curve from 0h to the last measured point 24h [AUC((0-24))], area under the curve from 0h to infinite time [AUC((0-∞))], peak plasma concentration (C(max) ), time to reach C(max) (t(max) ), oral clearance (CL), oral volume of distribution (V(d)) and elimination half-life (t(1/2) ), were determined following a single oral dose of losartan. The t(1/2) values of losartan and its active carboxylic acid metabolite E-3174 showed significant differences across the five ethnicities. After normalization by weight, no ethnicity-based difference was noted in the pharmacokinetic parameters of losartan. However, there were significant differences in C(max) and V(d) of the active carboxylic acid metabolite E-3174 for Han and Mongolian subjects, compared with the other three ethnic groups. There was a high linear correlation between weight and C(max) , AUC((0-24)) , AUC((0-∞)) , CL and V(d) . Ethnicity was associated with significant differences in the single-dose pharmacokinetics of losartan's active carboxylic acid metabolite E-3174 in healthy subjects of the five main ethnic groups in China.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054959079

Download citation: RISBibTeXText

PMID: 21777404

DOI: 10.1111/j.1365-2710.2011.01279.x


Related references

Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174. International Journal of Clinical Pharmacology and Therapeutics 50(9): 683-689, 2013

Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats. Die Pharmazie 68(11): 882-888, 2014

Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. European Journal of Clinical Pharmacology 65(6): 585-591, 2009

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clinical Pharmacology and Therapeutics 71(1): 89-98, 2002

Prediction of Losartan-Active Carboxylic Acid Metabolite Exposure Following Losartan Administration Using Static and Physiologically Based Pharmacokinetic Models. Journal of Pharmaceutical Sciences 106(9): 2758-2770, 2017

The effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects. Journal of Clinical Pharmacology 46(3): 310-320, 2006

A convenient synthesis by microwave irradiation of an active metabolite (EXP-3174) of losartan. Tetrahedron Letters 44(6): 1149-1152, 2003

Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174. Clinical Pharmacology and Therapeutics 59(3): 268-274, 1996

The kinetics of losartan and its active metabolite EXP 3174 in rats Intestinal vs hepatic processes. Pharmazie 53(3 Suppl. 1): 13, 1998

Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. Journal of Pharmacy and Pharmacology 62(7): 908-914, 2011

Characterisation of central and peripheral tissue distribution of the angiotensin II antagonist losartan and its active metabolite EXP 3174 in the rat. European Journal of Pharmaceutical Sciences 2(1-2): 161, 1994

Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clinical Pharmacology and Therapeutics 65(3): 348-352, 1999

The metabolism of losartan to the active metabolite E-3174 in subjects who are extensive and poor metabolizers of debrisoquine or mephenytoin. British Journal of Clinical Pharmacology 43(2): 215, 1997

Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers. British Journal of Pharmacology 129(6): 1235-1243, 2000

Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure. Hypertension Research 24(1): 65-74, 2001